TNF and congenital rubella syndrome: In anti-CD3 bispecific antibody therapy, adalimumab (anti-TNF-α drug) prevents macrophage activation and effectively mitigates CRS.61 Furthermore, the effect of adalimumab on COVID-19 patients has also been investigated.171